

1. [Need to improve medical delivery system: Govt](#) – Press Trust of India

The government today stressed on the need for "radically" improving the medical delivery system and make healthcare provisions patient centric. Health secretary C K Mishra said re-engineering the three pillars - people, processes and technology are the key to provide quality healthcare to all.

He was speaking at the annual healthcare conference, 'FICCI HEAL' on the theme 'Re-engineering Indian Healthcare' organised by FICCI in association with National Health Mission.

1. [Need to improve medical delivery system: Govt](#) – Press Trust of India
2. [Pharmaceutical industry growth to remain moderate, says Icra](#) – Business Standard
3. [IMA opposes move to scrap MCI](#) – The Hindu
4. [Karnataka approves amendments to aerospace, pharma policies](#) – Business Standard
5. [Working towards 10-15% topline growth in next 5-6 years: A Vaidheesh, GSK Pharma](#) – The Economic Times
6. [Battle over stroke medicine between Boehringer and Gennova heats up at court](#) – The Economic Times
7. [What do patients know about generic biotech drugs?](#) – Reuters.com
8. [U.S. business rescues pharma cos in quarter one](#) – Zee Business (Online)

2. [Pharmaceutical industry growth to remain moderate, says Icra](#) – Business Standard

Growth of the domestic pharmaceutical industry is likely to remain moderate due to factors like slowdown in the US market, increased competition and generic adoption reaching saturation levels, rating agency Icrasaid today.

"The growth trajectory for domestic pharmaceutical industry is likely to remain moderate on back of slowing growth from US markets given the relatively moderate proportion of large size drugs going off patent, increased competition, generic adoption reaching saturation levels, regulatory overhang along with base effect catching up," Icrasaid in a report here.

3. [IMA opposes move to scrap MCI](#) – The Hindu

The Indian Medical Association (IMA), Mangaluru branch, and various other associations of specialist doctors have strongly criticised the Union government's move to replace the Medical Council of India (MCI) through the National Medical Commission and said the government cannot do away self-regulation of the profession.

A. Amritha Bhandary, president, IMA, Mangaluru, said the Union government, through Niti Aayog, has posted the draft National Medical Commission Bill, 2016, on the Aayog's website and invited objections to the same. She said organisations of different specialties of modern scientific medicine have decided to oppose the proposal in totality.

4. [Karnataka approves amendments to aerospace, pharma policies](#) – Business Standard

Karnatakacabinet today gave approval for amendments to industry-specific policies with an intention to maintain the state's leadership position in the aerospace and pharmaceutical sectors. Cabinet today also approved to bring amendments to Karnataka Industrial Policy 2014-19 to integrate certain aspects relating to pharmaceutical policy through a dedicated chapter on medical devices manufacturing enterprises, with an intention to support the sector in concurrence with assurances made in the Budget 2016-17.

5. [Working towards 10-15% topline growth in next 5-6 years: A Vaidheesh, GSK Pharma](#) – **The Economic Times**

In an exclusive interview with ET Now, A Vaidheesh, GSK Pharmaceuticals, says latest launches in vaccines, nutrition and preventive medicines targeted at rural India. The Indian domestic market has been growing at a good pace. The fixed dose combination episode that happened recently and also the price control definitely has had impact on the growth rate and that has had been a bit of a dampener on the top line as well as bottom line of the company.

6. [Battle over stroke medicine between Boehringer and Gennova heats up at court](#) – **The Economic Times**

German drug giant Boehringer Ingelheim has taken its fight over Pune-based Gennova Biopharmaceuticals' use of tenecteplase to the Indian court room. Days after a Kolkata-based neurologist sued the central drug regulator for approving the drug to treat strokes, the multinational has filed its own writ petition at the Delhi High Court to revoke its marketing authorisation. Globally, tenecteplase has only been indicated for heart attacks and the Drug Controller General of India's (DCGI) approval to Gennova for stroke treatment is the first such approval of its kind.

7. [What do patients know about generic biotech drugs?](#) – **Reuters.com**

Many patients haven't heard of "biosimilars," generic versions of complex biotech drugs, and even some who say they're familiar with these medicines may still be confused about them, a small European survey suggests.

Biotech drugs known as biologics are injected medicines; typically containing proteins like antibodies made from living cells, and often carry price tags north of \$100,000 a year. Copies of these biotech drugs are called biosimilars because they can have the same ingredients and recipe without being exact copies of the original brand-name therapy.

8. [U.S. business rescues pharma cos in quarter one](#) – **Zee Business (Online)**

American operations boosted top- and bottom-lines of pharma companies in India in the first quarter ended June 30, 2016. An analysis of the results of these companies shows that even as their revenues grew by 9.4%, at Rs 35,662 crore, it was boosted by an over 15% growth in the American market. Revenues, from India, grew 7.6% to Rs 7,863 crore. Domestic growth was impacted by the National list of Essential Medicines (NLEM) and Fixed Dose Combination dispute (FDC).